Bionsight selected as the finalist team in 2022 Merck Research Grants.

| 0

Bionsight was selected as the finalist 8 teams out of a total of 1147 applications with the category, AI for Predictive Diagnostics & Therapeutic Target Discovery.
Bionsight researches the chemoproteomics platform which is based on high-resolution mass spec.
Our chemoproteomics platform, Javelin detects protein-ligand interactions at a proteome-wide scale.
It has a wide range of applications from target identification, validation, high throughput screening, and novel target discovery.
We believe chemoproteomics is an emerging technology and has a lot of potential for drug-discovery.

Leave a Reply

Your email address will not be published. Required fields are marked *